Novartis’ Aimovig tops topiramate in migraine face-off
pharmaphorum
NOVEMBER 4, 2020
Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial. The company has exclusive rights to the sell Aimovig outside the US, where Amgen records sales, with the exception of Japan.
Let's personalize your content